SI1453966T1 - Postopek za proizvajanje rekombinantega polipeptida - Google Patents

Postopek za proizvajanje rekombinantega polipeptida

Info

Publication number
SI1453966T1
SI1453966T1 SI200231005T SI200231005T SI1453966T1 SI 1453966 T1 SI1453966 T1 SI 1453966T1 SI 200231005 T SI200231005 T SI 200231005T SI 200231005 T SI200231005 T SI 200231005T SI 1453966 T1 SI1453966 T1 SI 1453966T1
Authority
SI
Slovenia
Prior art keywords
producing
recombinant polypeptide
polypeptide
recombinant
Prior art date
Application number
SI200231005T
Other languages
English (en)
Inventor
Kurt Schorgendorfer
Jorg Windisch
Renate Kunert
Florian Unterluggauer
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23304597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1453966(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SI1453966T1 publication Critical patent/SI1453966T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI200231005T 2001-11-28 2002-11-26 Postopek za proizvajanje rekombinantega polipeptida SI1453966T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33386801P 2001-11-28 2001-11-28
PCT/EP2002/013297 WO2003046187A1 (en) 2001-11-28 2002-11-26 Method for producing a recombinant polypeptide
EP20020791720 EP1453966B1 (en) 2001-11-28 2002-11-26 Method for producing a recombinant polypeptide

Publications (1)

Publication Number Publication Date
SI1453966T1 true SI1453966T1 (sl) 2012-11-30

Family

ID=23304597

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200231005T SI1453966T1 (sl) 2001-11-28 2002-11-26 Postopek za proizvajanje rekombinantega polipeptida

Country Status (19)

Country Link
US (1) US20050084969A1 (sl)
EP (1) EP1453966B1 (sl)
JP (1) JP4723185B2 (sl)
KR (1) KR20040063937A (sl)
CN (1) CN1596310A (sl)
AU (1) AU2002358047A1 (sl)
BR (1) BR0214489A (sl)
CA (1) CA2468832A1 (sl)
HR (1) HRP20040477A2 (sl)
HU (1) HUP0500059A2 (sl)
IL (1) IL161909A0 (sl)
MX (1) MXPA04005191A (sl)
NO (1) NO20042173L (sl)
NZ (1) NZ533133A (sl)
PL (1) PL370550A1 (sl)
RU (1) RU2004119814A (sl)
SI (1) SI1453966T1 (sl)
WO (1) WO2003046187A1 (sl)
ZA (1) ZA200403802B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528195A (ja) * 2003-10-09 2007-10-11 デウン カンパニー，リミテッド 高シアル酸含量のヒトトロンボポエチンを精製する方法
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
WO2012077128A1 (en) * 2010-12-07 2012-06-14 Intas Biopharmaceuticals Limited A novel cell line development process to produce recombinant proteins using twin vector expression system
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
JP6050289B2 (ja) * 2013-07-11 2016-12-21 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2750721C2 (ru) 2017-03-10 2021-07-01 Ф. Хоффманн-Ля Рош Аг Способ получения мультиспецифических антител

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DE3624453A1 (de) * 1986-07-19 1988-01-28 Behringwerke Ag Verfahren zur herstellung von humanem antithrombin iii (atiii), dafuer geeignete vektoren und wirtszellen, so erhaltenes, biologisch aktives atiii und dieses enthaltende arzneimittel
EP0319206A3 (en) * 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
NZ533133A (en) 2006-02-24
EP1453966A1 (en) 2004-09-08
PL370550A1 (en) 2005-05-30
CN1596310A (zh) 2005-03-16
NO20042173L (no) 2004-08-11
AU2002358047A1 (en) 2003-06-10
ZA200403802B (en) 2005-07-01
JP4723185B2 (ja) 2011-07-13
WO2003046187A1 (en) 2003-06-05
IL161909A0 (en) 2005-11-20
JP2005510242A (ja) 2005-04-21
HUP0500059A2 (hu) 2005-04-28
CA2468832A1 (en) 2003-06-05
US20050084969A1 (en) 2005-04-21
HRP20040477A2 (en) 2005-06-30
BR0214489A (pt) 2004-10-19
RU2004119814A (ru) 2005-04-20
MXPA04005191A (es) 2005-04-29
KR20040063937A (ko) 2004-07-14
EP1453966B1 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
IL161909A0 (en) Method for producing a recombinant polypeptide
EP1229125A4 (en) PROCESS FOR PRODUCING A POLYPEPTIDE
EP1391518A4 (en) PROCESS FOR PEPTIDE MANUFACTURE
PT1353891T (pt) Processo de fabrico de bisfenol a
GB0221060D0 (en) Method for producing a fluoropolymer
IL162780A0 (en) Method for producing modified peptide
EP1270730A4 (en) PROCESS FOR THE PREPARATION OF A POLYPEPTIDE COMPRISING A DISULFIDE BINDING
EP1304376A4 (en) PROCESS FOR PRODUCING RECOMBINANT PROTEIN
GB2382224B (en) Method for producing a substrate arrangement
IL172332A0 (en) Method for producing a polypeptide
EP1273563A4 (en) PROCESS FOR PRODUCING BISPHENOL A
AU2003263161A8 (en) Method for making recombinant proteins
EP1273655A4 (en) METHOD FOR PRODUCING A RECOMBINANT PROTEIN
AUPQ568100A0 (en) A method for producing recombinant molecules
HUP0401197A3 (en) Method for producing 3-bromomethylbenzoic acids
AU2002356453A1 (en) Method for producing a recombinant protein using pollen
HUP0400981A3 (en) Polypeptide purification method
AU2002356339A8 (en) Soluble recombinant protein production
AU2002303418A1 (en) Methods for producing recombinant coronavirus
AU2001263895A1 (en) Method for producing recombinant expansins
GB0124351D0 (en) Method for producing a protein
GB0123129D0 (en) Method for producing a protein
AU2002247674A1 (en) Method for producing recombinant trypsin
GB0111442D0 (en) Method for preparing recombinant virus
AU2002353431A8 (en) Method of modification of a protein or polypeptide